MT1011
Phase 1Small molecule
MT1011 is one of 2 small molecule programs targeting Anticoagulant Therapy. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1 competitor in Anticoagulant Therapy
#DrugCompanyPhaseTrials
1Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
MT1011
SShaanxi Micot Pharmaceutical Technology Co., Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MT1011. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details